Metastasized cancer life expectancy
Pro Research Analysisby 
Searched over 200M research papers
Metastasized Cancer Life Expectancy
Impact of Metastatic Site on Life Expectancy in Prostate Cancer
The site of metastasis significantly influences the overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC). A comprehensive analysis of 8,820 men revealed that those with liver metastases had the poorest median OS at 13.5 months. In contrast, patients with lung metastases had a median OS of 19.4 months, while those with bone metastases had a median OS of 21.3 months. The best outcomes were observed in men with lymph node-only metastases, who had a median OS of 31.6 months.
Brain Metastases in Breast Cancer
Brain metastases (BMs) from breast cancer drastically reduce life expectancy. A study of 1,712 patients found that the median OS after BM diagnosis was 7.4 months. Patients with HER2-positive tumors had the longest median OS at 11.6 months, compared to 5.9 months for those with luminal-like tumors and 4.6 months for those with triple-negative tumors. Notably, HER2-positive patients who received anti-HER2 treatment had a significantly longer median OS of 17.1 months.
Surgical Outcomes for Brain Metastases from Lung Cancer
Surgical resection of brain metastases from non-small-cell lung cancer can extend survival. A review of 231 patients showed a median survival of 11 months post-surgery. Factors such as single metastatic lesions, supratentorial tumor location, and high pre-surgery performance scores were associated with better outcomes. However, the overall prognosis remains poor, with a 5-year survival rate of only 12.5%.
Predicting Life Expectancy with the TEACHH Model
The TEACHH model is a tool designed to predict life expectancy in patients with metastatic cancer receiving palliative radiotherapy. It helps identify patients with short (<3 months) and long (>1 year) life expectancies, aiding in personalized treatment planning.
Long-Term Survival in Colorectal Cancer with Liver Metastases
Patients with initially unresectable colorectal cancer liver metastases can achieve long-term survival through a combination of effective chemotherapy and surgery. In a study of 151 patients, those who underwent successful resection after chemotherapy had a median survival of 48 months, with a 5-year survival rate of 50%.
Liver Metastases from Breast Cancer
Liver metastases from breast cancer generally indicate a poor prognosis, with a median survival of less than 6 months. However, a subset of patients who undergo liver resection can achieve long-term survival. In a study of 17 women, the 5-year survival rate was 22%, with some patients remaining tumor-free for up to 12 years.
Management and Treatment of Brain Metastases
The treatment paradigm for brain metastases has evolved significantly. Historically, brain metastases were considered terminal, with a life expectancy of only 1 month. Advances in whole brain radiotherapy, surgical resection, and stereotactic radiosurgery have extended life expectancy to 4-6 months. Novel targeted therapies and immunotherapies are showing promise in further improving outcomes.
Challenges in Treating Cancer Metastasis
Cancer metastasis remains the leading cause of cancer-related deaths, accounting for about 90% of fatalities. Despite improvements in early diagnosis and primary tumor treatment, progress in treating metastasis has been limited. Current treatments include chemotherapy and radiotherapy, with new-generation drugs targeting specific biochemical pathways involved in metastasis.
Life Expectancy in Differentiated Thyroid Cancer
Differentiated thyroid carcinoma (DTC) generally has a good prognosis, but life expectancy is significantly reduced in patients aged 45 and older with extensive local invasion, lateral lymph node metastases, or distant metastases. In these patients, the relative cumulative survival rate drops significantly, especially in those over 60 years old.
Conclusion
The life expectancy of patients with metastasized cancer varies widely depending on the type of primary cancer, the site of metastasis, and the treatments available. While advancements in surgical techniques, radiotherapy, and targeted therapies have improved outcomes for some patients, the prognosis remains poor for many, highlighting the need for continued research and development of more effective treatments.
Sources and full results
Most relevant research papers on this topic